Description:

Statistical issues in the analysis and interpretation of composite endpoints in oncology

Cancer clinical trials are routinely designed on the basis of event-free survival time where the event of interest may represent a complication, metastasis, relapse, or progression. This talk is concerned with a number of statistical issues arising with use of such endpoints including the interpretation of composite endpoints, analyses involving dual censoring schemes for component endpoints, and the causal interpretation of effects. Remarks will also be made on the analysis of longitudinal and survival data. This is joint work with Leilei Zeng (Waterloo).